الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 101 |  |  |
| | | from | 101 | | |
Abstract
Bladder urothelial cancer (BC) is one of the most common genitourinary malignancies characterized by high prevalence and recurrence rates(1). BC includes non-muscle invasive bladder cancer (NMIBC) and muscle invasive bladder cancer (MIBC). 75–85 % of patients with BC initially present with NMIBC and it’s reported that 5-year recurrence rate of NMIBC ranges from 50% to 70% and 5-year progression rate ranges from 10% to 20% (2, 3).
In our study including NMIBC patients, recurrence and progression percentages were the same (19.23%). Regarding T1 NMIBC cases recurrence and progression percentages were (22.5%) and (25%) respectively. Regarding Ta NMIBC cases recurrence was observed in one case only and no progression was observed.